Clinical Trials Logo

FAP clinical trials

View clinical trials related to FAP.

Filter by:

NCT ID: NCT06387381 Recruiting - Clinical trials for Positron-Emission Tomography

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Start date: May 20, 2024
Phase: Early Phase 1
Study type: Interventional

As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.

NCT ID: NCT06189820 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

FAPIPET
Start date: March 9, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

NCT ID: NCT05873777 Recruiting - Clinical trials for Positron-Emission Tomography

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Start date: April 9, 2023
Phase: N/A
Study type: Interventional

As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET/CT.

NCT ID: NCT05692596 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Start date: October 6, 2022
Phase:
Study type: Observational

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

NCT ID: NCT05262855 Recruiting - Clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

FAPI-46 PDAC
Start date: May 2, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

NCT ID: NCT05262647 Recruiting - Liver Fibrosis Clinical Trials

18F-FAPI PET in the Diagnosis of Liver Fibrosis

Start date: December 12, 2021
Phase:
Study type: Observational [Patient Registry]

It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis. The point of the clinical trial is to evaluate the novel biomaker 18F-FAPI-04 by PET-CT scan in the evaluation of the hepatic fibrosis.

NCT ID: NCT03061591 Not yet recruiting - Clinical trials for Familial Adenomatous Polyposis

Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.

Start date: April 2017
Phase: Phase 2
Study type: Interventional

A Phase 2, randomized, double blind, placebo controlled trial for the effectivness of wholistic turmeric supplementation on polyp burden mong patients with Familial Adenomatouse Polyposis (FAP). Fourty Patients will be randomly assigned in a 1:1 ratio to recieve treatment with 8 capsuls (2*4 capsuls/day) of wholistic Turmeric capsules (Pukka herbs) or placebo for six months.

NCT ID: NCT02175004 Completed - Amyloidosis Clinical Trials

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Start date: June 26, 2014
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.

NCT ID: NCT01737398 Completed - Amyloidosis Clinical Trials

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Start date: March 15, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).

NCT ID: NCT00633607 Completed - Lynch Syndrome Clinical Trials

Hereditary Colorectal and Associated Tumor Registry Study

Start date: April 2012
Phase: N/A
Study type: Observational

After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Participants will also be asked for their permission for study investigators to access medical records and/or recontact them for updates to their medical and family histories. Data and biospecimens will be stored for potential future research projects.